Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
Palvella Therapeutics announced two poster presentations at the 2026 American Academy of Dermatology Annual Meeting highlighting advances in their rare skin disease pipeline. Key data include the innovative QTORIN™ rapamycin anhydrous gel formulation overcoming prior drug stability issues and positive Phase 3 results in microcystic lymphatic malfor…